表柔比星连同多西紫杉醇实施三阴乳腺癌化疗的临床研究(1)
摘要：目的 研究表柔比星连同多西紫杉醇作为新辅助化疗方案对三阴乳腺癌(TNBC)的临床效果。方法 抽选84例乳腺癌患者为此次研究观察对象，根据是否为三阴乳腺癌将患者分为对照组(非TNBC)与观察组(TNBC)各42例，两组均接受表柔比星连同多西紫杉醇(ET方案)化疗， 具体为表柔比星与多西紫杉醇(ET方案)：静脉滴注表柔比星90 mg/m2，d1，静滴多西紫杉醇75 mg/m2，以21 d为1个疗程。在完成化疗周期后16～20 d采取手术治疗，疗效的评估则在术前1～2 d进行。比较两组临床疗效的差异。結果 研究组的完全缓解率为50.00%相比较于对照组的26.20%显著更高(P<0.05)，且临床总缓解率为85.70%相比较于对照组的66.70%显著更高(P<0.05)。结论 三阴乳腺癌采取表柔比星连同多西紫杉醇作为新辅助化疗方案可获得更高的完全缓解率与总缓解率，疗效显著，建议临床加以推广。
关键词：表柔比星；多西紫杉醇；三阴乳腺癌
中图分类号：R737.9 文献标识码：A 文章编号：1006-1959(2017)14-0072-03
, http://www.100md.com
Clinical Study of Epirubicin Combined with Docetaxel in the Treatment of Three Negative Breast Cancer Chemotherapy
LI Qi-ju
(Department of Oncology，the First People's Hospital of Liangshan Yi Autonomous Prefecture，Xichang 615000，Sichuan，China)
Abstract：Objective To study the epirubicin and docetaxel as neoadjuvant chemotherapy on three negative breast cancer(TNBC)clinical effect. Methods 84 cases of breast cancer were selected as the study object，according to whether the three negative breast cancer patients were divided into control group(non TNBC)and observation group(TNBC=42)，two groups were treated with docetaxel and epirubicin(ET regimen)chemotherapy，specific to epirubicin and docetaxel(ET)：intravenous injection of epirubicin 90 mg/m2，d1，intravenous docetaxel 75 mg/m2，21 d for 1 courses.Surgery was performed 16 to 20 d after the completion of the chemotherapy cycle.The evaluation of the curative effect was performed 1 to 2 d before surgery. Comparison of the two groups of clinical efficacy differences.Results The complete remission rate was 50.00% compared with 26.20% in the control group were significantly higher(P<0.05)，and the total clinical response rate was 85.70% compared with 66.70% in the control group were significantly higher(P<0.05).Conclusion Three negative breast cancer by epirubicin and docetaxel as neoadjuvant chemotherapy can get a higher complete remission rate and total remission rate，obvious curative effect，it is suggested that clinical application should be promoted.
, 百拇医药
Key words：Epirubicin；Docetaxel；Three negative breast cancer
三阴乳腺癌(TNBC)是指雌激素受体、孕激素受体以及人表皮生长因子受体均不表达，其发生率在整个乳腺癌中约占20%左右。三阴乳腺癌的恶性程度较高，病情进展迅速，预后较差。而由于三阴乳腺癌三不表达的特点，其并不能从内分泌治疗与抗人表皮生长因子受体的靶向治疗中获益，因此化疗成为了三阴乳腺癌治疗的主要手段[1]。现阶段，临床用于三阴乳腺癌化疗的方案较多，但多是参考相关乳腺癌类型的研究结果来选择化疗方案进行治疗。为了进一步明确合适的辅助化疗方案，本次研究以表柔比星连同多西紫杉醇实施三阴乳腺癌化疗，取得满意成效，现总结报告如下。
1资料与方法
1.1一般资料
研究在获得医院伦理委员会审查并监督展开，抽选84例于2013年10月～2015年10月在我院接受治疗的乳腺癌患者，经空芯针活检病理检查证实，临床分期为Ⅱ～Ⅲ期；入选病例的预计生存期超过3个月，KPS评分超过70分，至少结果超过3个月的新辅助化疗，且有可测量的病灶；排除经胸片、肝脏彩超、骨扫描等证实有远处转移，有其他恶性肿瘤病史，严重心、肝、肾功能不全等不宜纳入的患者剔除。患者在入组时即被告知研究目的，并同意将数据供研究使用。患者的年龄27～62岁，平均年龄(47.8±4.2)岁。根据是否为三阴乳腺癌将患者分为对照组(非TNBC)与观察组(TNBC)各42例，两组患者的年龄、临床分期及肿瘤大小等一般临床资料无显著差异(P>0.05)，具有可比性。, 百拇医药(黎启菊)
关键词：表柔比星；多西紫杉醇；三阴乳腺癌
中图分类号：R737.9 文献标识码：A 文章编号：1006-1959(2017)14-0072-03
, http://www.100md.com
Clinical Study of Epirubicin Combined with Docetaxel in the Treatment of Three Negative Breast Cancer Chemotherapy
LI Qi-ju
(Department of Oncology，the First People's Hospital of Liangshan Yi Autonomous Prefecture，Xichang 615000，Sichuan，China)
Abstract：Objective To study the epirubicin and docetaxel as neoadjuvant chemotherapy on three negative breast cancer(TNBC)clinical effect. Methods 84 cases of breast cancer were selected as the study object，according to whether the three negative breast cancer patients were divided into control group(non TNBC)and observation group(TNBC=42)，two groups were treated with docetaxel and epirubicin(ET regimen)chemotherapy，specific to epirubicin and docetaxel(ET)：intravenous injection of epirubicin 90 mg/m2，d1，intravenous docetaxel 75 mg/m2，21 d for 1 courses.Surgery was performed 16 to 20 d after the completion of the chemotherapy cycle.The evaluation of the curative effect was performed 1 to 2 d before surgery. Comparison of the two groups of clinical efficacy differences.Results The complete remission rate was 50.00% compared with 26.20% in the control group were significantly higher(P<0.05)，and the total clinical response rate was 85.70% compared with 66.70% in the control group were significantly higher(P<0.05).Conclusion Three negative breast cancer by epirubicin and docetaxel as neoadjuvant chemotherapy can get a higher complete remission rate and total remission rate，obvious curative effect，it is suggested that clinical application should be promoted.
, 百拇医药
Key words：Epirubicin；Docetaxel；Three negative breast cancer
三阴乳腺癌(TNBC)是指雌激素受体、孕激素受体以及人表皮生长因子受体均不表达，其发生率在整个乳腺癌中约占20%左右。三阴乳腺癌的恶性程度较高，病情进展迅速，预后较差。而由于三阴乳腺癌三不表达的特点，其并不能从内分泌治疗与抗人表皮生长因子受体的靶向治疗中获益，因此化疗成为了三阴乳腺癌治疗的主要手段[1]。现阶段，临床用于三阴乳腺癌化疗的方案较多，但多是参考相关乳腺癌类型的研究结果来选择化疗方案进行治疗。为了进一步明确合适的辅助化疗方案，本次研究以表柔比星连同多西紫杉醇实施三阴乳腺癌化疗，取得满意成效，现总结报告如下。
1资料与方法
1.1一般资料
研究在获得医院伦理委员会审查并监督展开，抽选84例于2013年10月～2015年10月在我院接受治疗的乳腺癌患者，经空芯针活检病理检查证实，临床分期为Ⅱ～Ⅲ期；入选病例的预计生存期超过3个月，KPS评分超过70分，至少结果超过3个月的新辅助化疗，且有可测量的病灶；排除经胸片、肝脏彩超、骨扫描等证实有远处转移，有其他恶性肿瘤病史，严重心、肝、肾功能不全等不宜纳入的患者剔除。患者在入组时即被告知研究目的，并同意将数据供研究使用。患者的年龄27～62岁，平均年龄(47.8±4.2)岁。根据是否为三阴乳腺癌将患者分为对照组(非TNBC)与观察组(TNBC)各42例，两组患者的年龄、临床分期及肿瘤大小等一般临床资料无显著差异(P>0.05)，具有可比性。, 百拇医药(黎启菊)
参见：首页 > 医疗版 > 疾病专题 > 普通外科 > 乳腺癌